In This Article:
Release Date: May 12, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Sangamo Therapeutics Inc (NASDAQ:SGMO) signed a significant license agreement with Eli Lilly, potentially worth up to $1.4 billion in milestone payments.
-
The company is advancing its neurology pipeline, with preparations for a Phase 1/2 study of ST 503 for chronic neuropathic pain.
-
Sangamo has achieved important clinical and regulatory milestones for its Fabry disease program, with a pivotal data readout expected soon.
-
The company has reduced non-GAAP operating expenses by 50% year-on-year, demonstrating financial discipline.
-
Sangamo is actively engaging in promising business development discussions, indicating ongoing interest in its technology platforms.
Negative Points
-
Sangamo Therapeutics Inc (NASDAQ:SGMO) requires additional capital to fund its operations and achieve proof of concept in its programs.
-
The company is reliant on securing a commercial partnership for its Fabry disease program to ensure long-term funding.
-
There is uncertainty regarding the statistical analysis plan for the EGFR data, which is crucial for regulatory submissions.
-
The company faces challenges in the broader macroeconomic landscape, including potential impacts from drug pricing discussions.
-
Sangamo's immediate cash runway is limited, necessitating a recent equity offering to extend its financial runway.
Q & A Highlights
Q: Could you provide more color on what exactly you plan to show in the top line EGFR data? Will you show just the EGFR slope or other quality of life endpoints? Also, will there be an NHS analysis to contextualize the improvements in EGFR? A: We will share the updated mean EGFR slope in the top line data and comment on additional information at a later date. We have agreed with the FDA on our statistical analysis plan, but we are not commenting on specifics at this time.
Q: How many potential partners are you currently in conversations with regarding a potential Fabry partnership, and what can you tell us about those discussions? A: We are in discussions with multiple potential partners. The recent Type B meeting with the FDA was helpful, providing a clear path for CMC, which is crucial for any gene therapy BLA and approval.
Q: Given the current administration's concern around drug pricing, how do you think that will impact gene therapy uptake and pricing in the US and abroad? A: There is a long way to go in discussions around drug pricing. The pharmaceutical industry is important in America, and BIO will be having detailed conversations with the administration to find a productive way forward.